ReviewJournal of clinical and experimental hepatology
Gallstone Disease in Cirrhosis-Pathogenesis and Management.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Association between albumin-bilirubin score and gallstones: exploring the potential mediating role of body mass index based on NHANES 2017-2020.Internal and emergency medicine · 2026Article
- Article
- Association between the albumin-bilirubin score and gallstone prevalence: evidence from NHANES and an independent hospital-based cohort.Frontiers in medicine · 2026Article
- Case report of pyloric obstruction caused by giant gallbladder compression with literature review.Frontiers in surgery · 2026Article
- Cystic Duct Stenting Versus Other Treatment Modalities for the Management of Acute Cholecystitis in Patients with Decompensated Cirrhosis.Digestive diseases and sciences · 2025Article
- Evaluating the liver fibrosis and waist-to-height ratio(LFWHR) as a gallstone disease predictor: a nomogram model and SHAP analysis.Scientific reports · 2025Article
- Shared genetic architecture of non-viral cirrhosis with several pleiotropic traits: A nested case-control study in the UK Biobank.Liver international communications · 2024Article
- Associations of gallbladder and gallstone parameters with clinical outcomes in patients with cirrhosis.Journal of translational internal medicine · 2024Article
- Physical activity and risk of cholelithiasis: a narrative review.Frontiers in medicine · 2024Review
- Hepatitis E Virus Infection Caused Elevation of Alanine Aminotransferase Levels in a Patient with Chronic Hepatitis B and Choledocholithiasis.Reports (MDPI) · 2023Article
- Identification of Intestinal Microbial Community in Gallstone Patients with Metagenomic Next-Generation Sequencing.Diagnostics (Basel, Switzerland) · 2023Article
- Minimally invasive treatment of cirrhotic secondary hypersplenism with high-intensity focused ultrasound.Scientific reports · 2022Article
- Surgical Risk Assessment in Patients with Chronic Liver Diseases.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallstones are more common in patients with cirrhosis of the liver, and the incidence increases with severity of liver disease. Pigment stones are the most frequent type of gallstones (GSs) in cirrhotics, and majority remain asymptomatic. Hepatitis C virus infection and nonalcoholic fatty liver disease are the underlying etiologies of liver diseases that most often associated with GSs. Multiple altered mechanisms in cirrhosis such as chronic hemolysis due to hypersplenism, reduced bile acid synthesis and transport, decreased cholesterol secretion, decreased apolipoprotein A-I and A-II secretion, gallbladder hypo-motility, autonomic dysfunction, and portal hypertension collectively lead to increased risk of lithogenesis. Asymptomatic GSs should be followed up closely and offered laparoscopic cholecystectomy once symptomatic in Child-Pugh class A and B patients. The model for the end-stage liver disease score is the best predictor of the outcome after cholecystectomy. In patients of Child-Pugh class C, conservative or minimally invasive approaches should be used to treat complications of GSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.